Echo said it will enroll up to 30 critical care patients and will then compare the data received from its Symphony tCGM System with the YSI 2300 STAT Plus Glucose Analyzer.

The data pairs collected will be used in the analyses, by taking frequent reference glucose measurements for 24 hours, and will be blinded to study subjects and study personnel.

The accuracy of the Symphony will be evaluated by the data relative to the compared blood glucose values.

Echo Therapeutics chairman and CEO Patrick Mooney said the goal of these trials is to demonstrate Symphony’s performance in the large and emerging critical care market for non-invasive continuous glucose monitoring.

"We believe that Symphony addresses this unmet need, potentially improving patient outcomes," Mooney said.